Date: 2014-06-23
Type of information: Licensing agreement
Compound: GlymaxX® Antibody Glyco-Engineering technology
Company: ProBioGen (Germany) Novartis (Switzerland)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity is an important antibody function leading to selectively killing target cells, i.e. cancer cells or pathogen-infected cells. ADCC enhancement has the potential to increase the therapeutic effect and/or to greatly reduce antibody dosage requirements, resulting in fewer side-effects and treatment costs. The absence of fucose enhances ADCC. The GlymaxX® technology, developed by ProBioGen, prevents the addition of this sugar to the N-linked antibody carbohydrate part by antibody producing cells. The GlymaxX® technology is based on the introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. The GlymaxX® technology is universally applicable, simple and potent, and can be rapidly applied to any existing antibody producer cell line, or can be included into any new cell line development.
Disease:
Details: * On June 23, 2014, ProBioGen announced that it has signed a non-exclusive commercial multi-product licensing agreement with Novartis on its GlymaxX® Antibody Glyco-Engineering technology. Novartis will apply the technology for manufacturing of selected ADCC activity-enhanced (Antibody-Dependent Cell-Mediated Cytotoxicity) antibodies in clinical and pre-clinical development. Under the terms of the license agreement, ProBioGen grants Novartis non-exclusive rights to use the GlymaxX® technology for an undisclosed number of clinical and pre-clinical development programs.
Financial terms: Financial details were not disclosed.
Latest news:
